IDEXX Laboratories, Inc. (IDXX)
USD 410.76
(-3.82%)
USD 410.76
(-3.82%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 2.18 Billion USD | 9.26% |
| 2022 | 2 Billion USD | 6.08% |
| 2021 | 1.88 Billion USD | 20.27% |
| 2020 | 1.57 Billion USD | 15.05% |
| 2019 | 1.36 Billion USD | 9.99% |
| 2018 | 1.24 Billion USD | 13.14% |
| 2017 | 1.09 Billion USD | 12.5% |
| 2016 | 975.43 Million USD | 9.57% |
| 2015 | 890.27 Million USD | 9.09% |
| 2014 | 816.11 Million USD | 7.94% |
| 2013 | 756.11 Million USD | 8.15% |
| 2012 | 699.14 Million USD | 8.14% |
| 2011 | 646.5 Million USD | 11.73% |
| 2010 | 578.62 Million USD | 9.95% |
| 2009 | 526.28 Million USD | -0.66% |
| 2008 | 529.76 Million USD | 14.29% |
| 2007 | 463.52 Million USD | 22.13% |
| 2006 | 379.52 Million USD | 17.54% |
| 2005 | 322.9 Million USD | 15.73% |
| 2004 | 279.01 Million USD | 21.15% |
| 2003 | 230.3 Million USD | 19.5% |
| 2002 | 192.72 Million USD | 5.12% |
| 2001 | 183.33 Million USD | -6.78% |
| 2000 | 196.65 Million USD | 2.8% |
| 1999 | 191.3 Million USD | 7.65% |
| 1998 | 177.7 Million USD | 24.09% |
| 1997 | 143.2 Million USD | -13.11% |
| 1996 | 164.8 Million USD | 45.33% |
| 1995 | 113.4 Million USD | 45.95% |
| 1994 | 77.7 Million USD | 31.92% |
| 1993 | 58.9 Million USD | 63.61% |
| 1992 | 36 Million USD | 92.51% |
| 1991 | 18.7 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 593.07 Million USD | 12.72% |
| 2024 Q2 | 620.88 Million USD | 4.69% |
| 2024 Q3 | 594.31 Million USD | -4.0% |
| 2023 Q3 | 547.98 Million USD | -4.34% |
| 2023 Q2 | 572.85 Million USD | 5.5% |
| 2023 Q1 | 542.97 Million USD | 11.97% |
| 2023 FY | 2.18 Billion USD | 9.26% |
| 2023 Q4 | 526.16 Million USD | -3.98% |
| 2022 Q3 | 506.62 Million USD | -1.44% |
| 2022 Q1 | 498.75 Million USD | 9.27% |
| 2022 Q2 | 514.03 Million USD | 3.06% |
| 2022 FY | 2 Billion USD | 6.08% |
| 2022 Q4 | 484.92 Million USD | -4.28% |
| 2021 Q4 | 456.42 Million USD | -3.49% |
| 2021 Q1 | 470.78 Million USD | 14.96% |
| 2021 Q2 | 489.3 Million USD | 3.94% |
| 2021 Q3 | 472.92 Million USD | -3.35% |
| 2021 FY | 1.88 Billion USD | 20.27% |
| 2020 Q4 | 409.5 Million USD | -3.1% |
| 2020 Q1 | 359.59 Million USD | 8.59% |
| 2020 FY | 1.57 Billion USD | 15.05% |
| 2020 Q2 | 379.34 Million USD | 5.49% |
| 2020 Q3 | 422.6 Million USD | 11.41% |
| 2019 Q1 | 331.59 Million USD | 10.4% |
| 2019 FY | 1.36 Billion USD | 9.99% |
| 2019 Q4 | 331.14 Million USD | -4.0% |
| 2019 Q3 | 344.95 Million USD | -3.61% |
| 2019 Q2 | 357.85 Million USD | 7.92% |
| 2018 Q4 | 300.36 Million USD | -1.73% |
| 2018 FY | 1.24 Billion USD | 13.14% |
| 2018 Q2 | 332.43 Million USD | 9.68% |
| 2018 Q1 | 303.09 Million USD | 11.24% |
| 2018 Q3 | 305.64 Million USD | -8.06% |
| 2017 Q1 | 258.19 Million USD | 7.3% |
| 2017 FY | 1.09 Billion USD | 12.5% |
| 2017 Q4 | 272.47 Million USD | -0.56% |
| 2017 Q2 | 292.71 Million USD | 13.37% |
| 2017 Q3 | 274 Million USD | -6.39% |
| 2016 Q1 | 227.53 Million USD | 4.52% |
| 2016 FY | 975.43 Million USD | 9.57% |
| 2016 Q4 | 240.62 Million USD | -2.47% |
| 2016 Q3 | 246.73 Million USD | -5.3% |
| 2016 Q2 | 260.54 Million USD | 14.51% |
| 2015 Q3 | 224.27 Million USD | -3.64% |
| 2015 FY | 890.27 Million USD | 9.09% |
| 2015 Q1 | 215.54 Million USD | 18.32% |
| 2015 Q2 | 232.75 Million USD | 7.99% |
| 2015 Q4 | 217.69 Million USD | -2.93% |
| 2014 Q3 | 213.33 Million USD | -2.37% |
| 2014 Q1 | 202.09 Million USD | 7.12% |
| 2014 FY | 816.11 Million USD | 7.94% |
| 2014 Q2 | 218.51 Million USD | 8.13% |
| 2014 Q4 | 182.16 Million USD | -14.61% |
| 2013 Q1 | 183.97 Million USD | 8.83% |
| 2013 FY | 756.11 Million USD | 8.15% |
| 2013 Q4 | 188.66 Million USD | 1.55% |
| 2013 Q3 | 185.78 Million USD | -6.03% |
| 2013 Q2 | 197.69 Million USD | 7.46% |
| 2012 Q3 | 170.63 Million USD | -7.61% |
| 2012 Q2 | 184.68 Million USD | 5.67% |
| 2012 Q1 | 174.77 Million USD | 10.0% |
| 2012 FY | 699.14 Million USD | 8.14% |
| 2012 Q4 | 169.05 Million USD | -0.93% |
| 2011 Q4 | 158.88 Million USD | 0.13% |
| 2011 FY | 646.5 Million USD | 11.73% |
| 2011 Q1 | 154.92 Million USD | 7.01% |
| 2011 Q2 | 174.03 Million USD | 12.33% |
| 2011 Q3 | 158.66 Million USD | -8.83% |
| 2010 FY | 578.62 Million USD | 9.95% |
| 2010 Q4 | 144.77 Million USD | 1.8% |
| 2010 Q3 | 142.2 Million USD | -4.74% |
| 2010 Q2 | 149.28 Million USD | 4.86% |
| 2010 Q1 | 142.36 Million USD | 7.09% |
| 2009 FY | 526.28 Million USD | -0.66% |
| 2009 Q3 | 130.47 Million USD | -5.75% |
| 2009 Q2 | 138.44 Million USD | 11.26% |
| 2009 Q1 | 124.43 Million USD | 3.25% |
| 2009 Q4 | 132.93 Million USD | 1.88% |
| 2008 FY | 529.76 Million USD | 14.29% |
| 2008 Q3 | 128.14 Million USD | -15.28% |
| 2008 Q2 | 151.26 Million USD | 16.5% |
| 2008 Q4 | 120.52 Million USD | -5.95% |
| 2008 Q1 | 129.83 Million USD | 6.21% |
| 2007 Q3 | 118.47 Million USD | 3.73% |
| 2007 Q2 | 114.22 Million USD | 5.2% |
| 2007 Q1 | 108.57 Million USD | 12.79% |
| 2007 FY | 463.52 Million USD | 22.13% |
| 2007 Q4 | 122.24 Million USD | 3.18% |
| 2006 FY | 379.52 Million USD | 17.54% |
| 2006 Q4 | 96.26 Million USD | -1.97% |
| 2006 Q3 | 98.19 Million USD | -0.85% |
| 2006 Q2 | 99.03 Million USD | 15.12% |
| 2006 Q1 | 86.02 Million USD | 1.31% |
| 2005 Q1 | 76.08 Million USD | 10.4% |
| 2005 FY | 322.9 Million USD | 15.73% |
| 2005 Q4 | 84.91 Million USD | 4.41% |
| 2005 Q3 | 81.32 Million USD | 0.94% |
| 2005 Q2 | 80.57 Million USD | 5.91% |
| 2004 Q2 | 72 Million USD | 7.39% |
| 2004 Q3 | 71.05 Million USD | -1.31% |
| 2004 Q4 | 68.91 Million USD | -3.02% |
| 2004 FY | 279.01 Million USD | 21.15% |
| 2004 Q1 | 67.04 Million USD | 11.59% |
| 2003 Q2 | 59.67 Million USD | 15.95% |
| 2003 Q1 | 51.46 Million USD | 5.01% |
| 2003 Q3 | 59.09 Million USD | -0.97% |
| 2003 Q4 | 60.08 Million USD | 1.68% |
| 2003 FY | 230.3 Million USD | 19.5% |
| 2002 Q4 | 49 Million USD | -3.45% |
| 2002 Q3 | 50.76 Million USD | 1.73% |
| 2002 Q2 | 49.89 Million USD | 15.87% |
| 2002 Q1 | 43.06 Million USD | -1.08% |
| 2002 FY | 192.72 Million USD | 5.12% |
| 2001 FY | 183.33 Million USD | -6.78% |
| 2001 Q2 | 49.51 Million USD | 1.02% |
| 2001 Q3 | 46.42 Million USD | -6.24% |
| 2001 Q4 | 43.53 Million USD | -6.22% |
| 2001 Q1 | 49.01 Million USD | 1.48% |
| 2000 Q2 | 51.54 Million USD | 4.91% |
| 2000 FY | 196.65 Million USD | 2.8% |
| 2000 Q4 | 48.29 Million USD | 1.3% |
| 2000 Q3 | 47.68 Million USD | -7.5% |
| 2000 Q1 | 49.13 Million USD | 3.44% |
| 1999 Q2 | 48.8 Million USD | -0.61% |
| 1999 Q3 | 45.7 Million USD | -6.35% |
| 1999 Q4 | 47.5 Million USD | 3.94% |
| 1999 FY | 191.3 Million USD | 7.65% |
| 1999 Q1 | 49.1 Million USD | 6.51% |
| 1998 Q2 | 44.3 Million USD | 1.84% |
| 1998 Q3 | 43.8 Million USD | -1.13% |
| 1998 Q1 | 43.5 Million USD | 20.5% |
| 1998 FY | 177.7 Million USD | 24.09% |
| 1998 Q4 | 46.1 Million USD | 5.25% |
| 1997 FY | 143.2 Million USD | -13.11% |
| 1997 Q1 | 34.6 Million USD | -26.54% |
| 1997 Q2 | 32.7 Million USD | -5.49% |
| 1997 Q3 | 39.6 Million USD | 21.1% |
| 1997 Q4 | 36.1 Million USD | -8.84% |
| 1996 FY | 164.8 Million USD | 45.33% |
| 1996 Q2 | 38.7 Million USD | 10.57% |
| 1996 Q1 | 35 Million USD | 11.11% |
| 1996 Q4 | 47.1 Million USD | 7.29% |
| 1996 Q3 | 43.9 Million USD | 13.44% |
| 1995 Q3 | 29.1 Million USD | 2.46% |
| 1995 Q4 | 31.5 Million USD | 8.25% |
| 1995 FY | 113.4 Million USD | 45.95% |
| 1995 Q1 | 24.2 Million USD | 10.0% |
| 1995 Q2 | 28.4 Million USD | 17.36% |
| 1994 Q2 | 19.1 Million USD | 11.7% |
| 1994 Q3 | 19.4 Million USD | 1.57% |
| 1994 Q4 | 22 Million USD | 13.4% |
| 1994 FY | 77.7 Million USD | 31.92% |
| 1994 Q1 | 17.1 Million USD | 1.79% |
| 1993 FY | 58.9 Million USD | 63.61% |
| 1993 Q2 | 14.5 Million USD | 26.09% |
| 1993 Q4 | 16.8 Million USD | 9.09% |
| 1993 Q1 | 11.5 Million USD | 15.0% |
| 1993 Q3 | 15.4 Million USD | 6.21% |
| 1992 Q1 | 7 Million USD | 16.67% |
| 1992 Q4 | 10 Million USD | 3.09% |
| 1992 Q3 | 9.7 Million USD | 3.19% |
| 1992 FY | 36 Million USD | 92.51% |
| 1992 Q2 | 9.4 Million USD | 34.29% |
| 1991 Q1 | 6.3 Million USD | 0.0% |
| 1991 FY | 18.7 Million USD | 0.0% |
| 1991 Q3 | 4.6 Million USD | 4.55% |
| 1991 Q2 | 4.4 Million USD | -30.16% |
| 1991 Q4 | 6 Million USD | 30.43% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Bionano Genomics, Inc. | 9.56 Million USD | -22793.268% |
| Prenetics Global Limited | 8.82 Million USD | -24701.79% |
| Star Equity Holdings, Inc. | 11.92 Million USD | -18262.988% |
| CareDx, Inc | 178.32 Million USD | -1128.078% |
| Exact Sciences Corporation | 1.84 Billion USD | -18.664% |
| Exagen Inc. | 29.45 Million USD | -7334.716% |
| Inotiv, Inc. | 165.44 Million USD | -1223.701% |
| Guardant Health, Inc. | 336.89 Million USD | -550.043% |
| Biodesix, Inc. | 36.07 Million USD | -5970.266% |
| BioNexus Gene Lab Corp. | 1.32 Million USD | -164621.572% |
| Precipio, Inc. | 6.01 Million USD | -36290.329% |
| iSpecimen Inc. | 5.1 Million USD | -42774.041% |
| Natera, Inc. | 492.74 Million USD | -344.447% |
| Aspira Women's Health Inc. | 5.26 Million USD | -41518.586% |
| Standard BioTools Inc. | 50.45 Million USD | -4240.872% |
| 23andMe Holding Co. | 99.37 Million USD | -2103.699% |
| Castle Biosciences, Inc. | 174.8 Million USD | -1152.8% |
| Personalis, Inc. | 18.2 Million USD | -11927.515% |
| Aclaris Therapeutics, Inc. | 13.16 Million USD | -16530.999% |
| Applied DNA Sciences, Inc. | 5.53 Million USD | -39477.065% |
| OpGen, Inc. | -90.69 Thousand USD | 2414780.133% |
| T2 Biosystems, Inc. | -8.17 Million USD | 26905.018% |
| Myriad Genetics, Inc. | 476.4 Million USD | -359.691% |
| ICON Public Limited Company | 1.81 Billion USD | -20.708% |
| NeoGenomics, Inc. | 244.6 Million USD | -795.312% |
| Star Equity Holdings, Inc. | 11.92 Million USD | -18262.988% |
| RadNet, Inc. | 93 Million USD | -2254.806% |
| MDxHealth SA | 43.92 Million USD | -4885.249% |
| Psychemedics Corporation | 8.41 Million USD | -25930.786% |
| Illumina, Inc. | 2.74 Billion USD | 20.191% |
| Check-Cap Ltd. | -212 Thousand USD | 1033104.717% |
| Twist Bioscience Corporation | 133.34 Million USD | -1542.285% |
| DarioHealth Corp. | 5.98 Million USD | -36497.092% |
| Fulgent Genetics, Inc. | 104.45 Million USD | -1996.548% |
| Sera Prognostics, Inc. | 96 Thousand USD | -2281118.75% |
| ENDRA Life Sciences Inc. | -275.45 Thousand USD | 795148.847% |
| OPKO Health, Inc. | 318.12 Million USD | -588.395% |
| Medpace Holdings, Inc. | 524.5 Million USD | -317.531% |
| Neogen Corporation | 463.9 Million USD | -372.078% |
| Intelligent Bio Solutions Inc. | 1.42 Million USD | -153514.623% |
| Prenetics Global Limited | 8.82 Million USD | -24701.79% |
| Mainz Biomed B.V. | 509.65 Thousand USD | -429593.187% |
| bioAffinity Technologies, Inc. | 791.61 Thousand USD | -276545.844% |
| Trinity Biotech plc | 19.45 Million USD | -11159.486% |
| Neuronetics, Inc. | 51.7 Million USD | -4135.509% |
| Sotera Health Company | 577.15 Million USD | -279.44% |
| bioAffinity Technologies, Inc. | 791.61 Thousand USD | -276545.844% |